Slingshot members are tracking this event:
Phase 2 open-label trial data of FG-3019 for Pancreatic cancer to be presented at 2016 Gastrointestinal Cancers Symposium of ASCO GI in January 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jan 22, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fg-3019, Pancreatic Cancer, Gastrointestinal Cancers Symposium